Physician profile
Christopher E Estel
NPI 1992016703
$7,733.61
in general payments reported to CMS, 2019-2025
32 companies · $993 in 2025
The $993 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,116 · 2020: $1,410 · 2021: $443 · 2022: $970 · 2023: $658 · 2024: $1,143 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,115.52 | 2019-2023 | |
| Cook Medical LLC | $885.64 | 2019-2025 | Advance, Tornado, Torcon Nb |
| Abbott Laboratories | $869.76 | 2020-2025 | Navitor |
| Angiodynamics, INC. | $728.42 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $620.15 | 2019-2024 | Repatha |
| Penumbra, INC. | $518.51 | 2019-2023 | Indigo System |
| Bard Peripheral Vascular, INC. | $490.17 | 2021-2025 | Rotarexs 6 F X 135 Cm, True Flow, Halo One Thin-Walled Guiding Sheath |
| Novartis Pharmaceuticals Corporation | $393.01 | 2019-2025 | |
| Medtronic, INC. | $374.89 | 2022-2024 | Ffrangio, Onyx Frontier, Telescope |
| E.R. Squibb & Sons, L.L.C. | $247.66 | 2022-2025 | Eliquis, Camzyos |
| Cardiovascular Systems INC. | $204.97 | 2019-2022 | |
| Acist Medical Systems, INC. | $198.57 | 2019-2025 | |
| Edwards Lifesciences Corporation | $147.29 | 2022-2024 | |
| Pfizer INC. | $145.68 | 2019-2024 | |
| Stryker Corporation | $133.90 | 2025 | Limflow System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $122.00 | 2025 | |
| Boston Scientific Corporation | $113.85 | 2022-2024 | Vigilant X4 Crt-D |
| Astrazeneca Pharmaceuticals LP | $91.90 | 2019-2022 | |
| Cvrx, INC. | $64.80 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $58.27 | 2019-2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $39.56 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.12 | 2023 | Lifevest |
| Cardiva Medical, INC. | $25.98 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $21.71 | 2019 | |
| Smith+Nephew, INC. | $17.80 | 2019 | |
| Biotronik INC. | $14.63 | 2025 | Acticor 7 Vr-T Dx |
| Inspire Medical Systems, INC. | $14.34 | 2023 | Inspire |
| Recor Medical INC | $13.12 | 2024 | Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals, LTD. | $12.84 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $12.32 | 2019 | |
| Neovasc Medical INC | $7.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Estel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.